Summary
Biopsy tissues of 52 patients with Ewing’s sarcoma of bone treated between 1983 and 1993 were examined immunohistochemically to determine the significance of p53 protein in diagnosis and prognosis of Ewing’s sarcoma. Mean age at diagnosis was 17 years (range 6–36) and minimum follow-up was 30 months. The tumours were located in the extremities and central bones in 35 and 17 patients respectively. Metastases were present in seven patients at diagnosis. Treatment consisted of chemotherapy, surgery and/or radiotherapy in all the patients. Overexpression of p53 protein was demonstrated in seven patients (14%). There was no relationship between expression of p53 and site of tumours. Patients who overexpressed p53 protein appeared to have more advanced diseases at diagnosis and poorer response to chemotherapy than those without p53 overexpression. The 5-year relapse-free survival and overall survival in patients without metastases at the time of diagnosis were 66% and 71%, respectively, in p53 protein-negative patients compared with 20% relapse-free and overall survival in those with p53 protein overexpression (P = 0.01). The poorer prognosis in p53 protein-positive patients was independent of site, local treatment or necrosis of the tumours (P < 0.05). Over-expression of p53 protein is an independent poor prognostic factor in Ewing’s sarcoma of bone.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Baas, I. O., Mulder, J. R., Offerhaus, G. J. A., Volgelstein, B. & Hamilton, S. R. (1994). An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 172: 5–12.
Bartek, J., Iggo, R., Gannon, J. & Lane, D. P. (1990). Genetic and immunocytochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 5: 893–899.
Cangir, A., Vietti, T. J., Gehan, E. A., Burgert, E. O., Thomas, P., Tefft, M., Nesbit, M. E., Kissane, J. & Pritchard, D. (1990). Ewing’s sarcoma metastatic at diagnosis. Cancer 66: 887–893.
Cattoretti, G., Becker, M. G. H., Key, G., Duchrow, M., Schluter, C., Galle, J. & Gerdes, J. (1992). Monoclonal antibodies against recombinant parts of ki-67 antigen (M1B1 and M1B3) detect proliferating cells in microwave processed fixed paraffin section. J Pathol 168: 357–363.
Cordon-Cardo, C., Latres, E., Drobnjak, M., Oliva, M. R., Pollack, D., Woodruff, J. M., Marechal, V., Chen, J., Brennan, M. F. & Levine, A. J. (1994). Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 54: 794–799.
Cox, D. R. (1972). Regression models and life-tables (with discussion). J R Stat Soc B 34: 187–220.
Davidoff, A. M., Humphery, P. A., Iglehart, J. D. & Marks, J. R. (1991). Genetic basis for p53 overexpression in human breast cancer. Proc Natl Acad Sci USA 88: 5006–5010.
Esrig, D., Spruck, III C. H., Nichols, P. W., Chaiwun, B., Steven, K., Groshen, S., Chen, S., Skinner, D. G., Jones, P. A. & Cote, R. J. (1993). p53 nuclear protein accumulation correlates with mutation in the p53 gene, tumour grade and stage in bladder cancer. Am J Pathol 143: 1389–1397.
Ewing, J. (1921). Diffuse endothelioma of bone. Proc N Y Pathol Soc 21: 17–24.
Glass, A. G. & Fraumeni, J. F. (1970). Epidemiology of bone cancer in children. J Natl Cancer Inst 44: 187–199.
Greenblatt, M. S., Bennett, W. P., Hollstein, M. & Harris, C. C. (1994). Mutations in the p53 tumour suppressor gene: clues to cancer aetiology and molecular pathogenesis. Cancer Res 54: 4855–4878.
Hsu, H., Tseng, H., Lai, P., Lee, P. & Peng, S. (1993). Expression of p53 gene in 184 unifocal hepatocellular carcinomas: association with tumour growth and invasiveness. Cancer Res 53: 4691–4694.
Huvos, A. G. (1991). Ewing’s sarcoma. In Bone Tumours: Diagnosis, Treatment and Prognosis, 2nd edn. Mitchell L (ed.), pp. 523–552, W B Saunders: Philadephia
Isola, J., Visakorpi, T., Holli, K. & Kallioniemi, O. (1992). Association of overexpression of tumour suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 84: 1109–1114.
Kaplan, F. L. & Meier, P. (1958). Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481.
Kovar, H., Auinger, A., Jug, G., Aryee, D., Zoubek, A., Salzer-Kuntschik, M. & Gadner, H. (1993). Narrow spectrum of infrequent p53 mutations and absence ofMDM 2 amplification in Ewing’s tumours. Oncogene 8: 2683–2690.
Lane, D. P. (1993). A death in the life of p53. Nature 362: 786–787.
Larsson, S. E. & Lorentzon, R. (1974). The geographic variation of the incidence of primary bone tumours in Sweden. J Bone Joint Surg 56A: 592–600.
Levine, A. J. (1992). The p53 tumour-suppressor gene. N Engl J Med 326: 1350–1351.
Mangham, D. C., Cannon, A., Li, X. Q., Komiya, S., Gebhardt, M. C., Springfield, D. S., Rosenberg, A. E. & Mankin, H. J. (1995). p53 overexpression in Ewing’s sarcoma/primitive neuroectodermal tumours is an uncommon event. J Clin Pathol Mol Pathol 48: M79–M82.
Mantel, N. (1966). Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163–170.
Mendenhall, C. M., Marcus, R. B., Enneking, W. F., Springfield, D. S., Thar, T. L. & Million, R. R. (1983). The prognostic significance of soft-tissue extension in Ewing’s sarcoma. Cancer 51: 913–917.
Price, C. H. G. & Jeffree, G. M. (1977). Incidence of bone sarcoma in SW England, 1946–74, in relation to age, sex, tumour site and histology. Br J Cancer 36: 511–522.
Sauer, R., Jurgens, H., Burgers, J. M., Dunst, J., Hawlicek, R. & Michaelis, J. (1987). Prognostic factors in the treatment of Ewing’s sarcoma. The Ewing’s Sarcoma Study Group of the German Society of Paediatric Oncology CESS 81. Radiat Oncol 10: 101–110.
Toguchida, J., Yamaguchi, T., Wadayama, B. I., Kotoura, Y., Yandell, D. W. & Yamamuro, T. (1993). p53 tumour suppressor gene as the frequent target for somatic and germ-line mutation in bone and soft tissue sarcoma. In Limb Salvage – Current Trends. Proceedings of the 7th International Symposium ISOLS, Singapore, Tan SK (ed.)
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Abudu, A., Mangham, D., Reynolds, G. et al. Overexpression of p53 protein in primary Ewing’s sarcoma of bone: relationship to tumour stage, response and prognosis. Br J Cancer 79, 1185–1189 (1999). https://doi.org/10.1038/sj.bjc.6690190
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690190
Keywords
This article is cited by
-
An international working group consensus report for the prioritization of molecular biomarkers for Ewing sarcoma
npj Precision Oncology (2022)
-
Precision medicine in Ewing sarcoma: a translational point of view
Clinical and Translational Oncology (2020)
-
Prognostic significance of p53 expression in malignant bone tumors: a meta-analysis
Tumor Biology (2013)
-
The clinical use of biomarkers as prognostic factors in Ewing sarcoma
Clinical Sarcoma Research (2012)
-
Histone deacetylase inhibitors enhance expression of NKG2D ligands in Ewing sarcoma and sensitize for natural killer cell-mediated cytolysis
Clinical Sarcoma Research (2012)